
BioMarin (BMRN) shares closed roughly 20% higher on Dec. 19 after announcing a $4.8 billion acquisition of Philadelphia-headquartered Amicus Therapeutics (FOLD).
The all-cash transaction values each FOLD share at $14.50, a 33% premium over their previous close, indicating BioMarin’s commitment to expanding its footprint in the rare disease market.